1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
JB Chemicals & Pharmaceuticals Ltd.

JB Chemicals & Pharmaceuticals Ltd.

2,408.90
INR
-97.10
(-3.87%)
44.55EPS
45.72P/E
331.46BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
55.35
61.77
68.81
77.18
82.31
97.8
109.44
130.62
156.83
403.04
222.5
248.58
259.44
263.98
Basic EPS, GAAP
3.63
5.92
9.57
10.71
8.24
11.77
17.1
28.98
24.93
53
35.66
42.45
45.16
45.15
Free Cash Flow per Basic Share
-4.39
3.27
-3.7
2.65
5.15
8.83
12.74
17.28
-34.72
-18.02
34.8
50.34
39.51
- -
Dividend per Share
1.76
1.75
11.06
0.34
0.62
1.27
8.86
4.74
8.25
16.5
10.13
15.26
19.94
- -
Book Value per Share
61.54
58.65
64.47
80.39
86.25
92.23
92.87
117.09
138.07
160.28
188.37
220.54
259.05
259.05
Tangible Book Value per Share
60.04
57.2
60.38
75.54
81.71
87.47
87.49
111.29
90.92
71.12
95.2
132.24
178.92
178.92
Basic Weighted Avg Shares
169
170
170
170
168
164
159
155
155
77
155
155
157
157
Sales/Revenue/Turnover
9,378
10,474
11,673
13,093
13,822
16,076
17,414
20,189
24,242
31,165
34,477
38,620
40,762
41,478
Operating Margin (%)
9.45
11.12
14.76
14.06
11.61
16.1
18.26
24.15
19.42
18.85
21.83
22.13
22.1
22.3
Depreciation Expense
280
386
412
472
570
556
663
687
727
1,144
1,383
1,710
1,825
1,825
Net Income, GAAP
615
1,004
1,625
1,841
1,383
1,935
2,720
4,480
3,854
4,098
5,526
6,596
7,095
7,095
Effective Tax Rate (%)
29.67
31.02
23.36
19.81
28.48
32.41
21.93
24.86
23.54
26.16
26.46
25.67
25.5
25.5
Profit Margin (%)
6.56
9.59
13.93
14.06
10.01
12.03
15.62
22.19
15.9
13.15
16.03
17.08
17.41
17.1
Working Capital
7,044
6,233
3,420
5,137
7,721
8,070
7,599
12,073
8,911
9,736
9,851
12,904
23,182
23,182
LT Debt
5
4
- -
- -
- -
- -
12
51
206
3,985
333
64
11
11
Total Equity
10,428
9,949
10,953
13,658
14,443
14,829
14,380
18,134
21,386
24,804
29,233
34,333
41,592
41,592
Return on Invested Capital (%)
5.66
8.96
13.47
13.64
8.02
11.86
16.16
24.22
17.8
16.55
17.43
18.84
17.2
17.65
Return on Capital (%)
5.79
9.14
14.12
13.89
9.71
13.14
18.37
27.17
19.18
16.62
18.41
19.74
18.72
18.72
Return on Common Equity (%)
5.96
9.85
15.55
14.79
9.86
13.24
18.66
27.61
19.54
17.76
20.45
20.75
18.69
18.69

Capital Structure

INR

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
192
- -
25
LT Borrowings
- -
- -
- -
LT Finance Leases
217
- -
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
157
157
161
Market Capitalization
267,733
285,058
331,457

Working Capital

INR

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
25,551
- -
29,094
Cash, Cash Equivalents & STI
9,014
- -
12,213
Accounts Receivable, Net
9,377
- -
7,809
Inventories
5,766
- -
6,834
Total Current Liabilities
6,742
- -
5,912
Payables & Accruals
- -
- -
- -
ST Debt
192
- -
25
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.66%
18.07%
21.14%
Free Cash Flow
-77.77%
-167.53%
-20.64%
Net Income, GAAP
18.77%
10.82%
7.56%
Sales/Revenue/Turnover
13.51%
15.37%
5.55%
Total Cash Common Dividend
92.01%
36.08%
32.17%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,962
8,817
8,445
8,252
34,477
2025
10,044
10,006
9,635
9,495
38,620
2026
10,939
10,849
10,647
9,042
40,762

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9.2
9.72
8.62
8.13
35.66
2025
11.39
11.24
10.46
9.36
42.45
2026
12.99
13.29
12.63
6.35
45.16

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
10.13
2025
- -
- -
- -
- -
15.26
2026
- -
- -
- -
- -
19.94

Company Description

Company Profile APIChatGPT
CEO
Suresh Amin
Full Time Employees
7,906
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Cnergy IT Park Mumbai MA India 400025
IPO Date
Feb 2, 1995
Website
jbpharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets a broad portfolio of pharmaceutical formulations across more than 20 therapeutic areas including gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynecology, dental care, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesics, dermatology, antivirals, lozenges, and contrast media; key brands encompass Rantac and Metrogyl in gastroenterology and anti-infectives, Cilacar and Nicardia in hypertension, Cadomer in wound care and dermatology, along with specialized offerings such as proton pump inhibitors, antibiotics in oral/injectable/topical forms, calcium channel blockers, DPP-4 inhibitors, ketoanalogues for renal care, lozenges as the third-largest global manufacturer, and contrast agents for imaging. The company operates primarily in India with distribution through 600,000 pharmacies nationwide, exports to over 40 regulated and semi-regulated markets including the USA, and maintains wholly owned subsidiaries in South Africa and Russia; it serves healthcare providers and patients via eight state-of-the-art manufacturing facilities compliant with USFDA and WHO standards, focusing on chronic therapies, contract development and manufacturing organization services particularly in medicated lozenges, and incremental innovation for lifecycle management. Founded in 1976 and headquartered in Mumbai, India, J. B. Chemicals & Pharmaceuticals has pursued aggressive inorganic growth through five acquisitions in India over the past two years including the Razel franchise from Glenmark in 2024 and approximately 15 ophthalmology drugs from Novartis for INR 1,089 crore in late 2024 to enter the high-growth ophthalmology segment comprising anti-infectives, anti-allergies, and glaucoma treatments effective from January 2027; most recently in June 2025, Torrent Pharmaceuticals agreed to acquire a controlling 46.39% stake from KKR for INR 11,917 crore at an equity valuation of INR 25,689 crore followed by a mandatory open offer and subsequent merger, pending regulatory approvals including from SEBI, CCI, and NCLT, to create a diversified platform enhancing Torrent's Indian branded formulations presence and JB's CDMO capabilities.